Ramucirumab, Erlotinib Combo Delays Disease Progression in NSCLC Trial

Treatment with ramucirumab (Cyramza) in combination with erlotinib significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer (NSCLC), according to new data from a phase 3 clinical trial.
Eli Lilly reported the findings from the phase 3 RELAY study evaluating the combination as a first-line therapy in patients with metastatic disease whose tumors have activating epidermal growth factor receptor (EGFR) mutations.
Currently, metastatic EGFR-mutated NSCLC is associated with poor survival rates and disease progression following acquired resistance from therapies. Tyrosine kinase inhibitors, such as erlotinib, are the current standard-of-care in this patient population.
“Despite recent treatment advances in metastatic EGFR-mutated non-small cell lung cancer, prognosis remains poor and there is an ongoing need for additional first-line treatment options to help patients with this deadly disease,” Maura Dickler, MD, vice president of late phase development at Lilly Oncology, said in a statement.
The RELAY trial, which was initiated in 2015, randomized 449 patients with a primary endpoint of progression-free survival and key secondary endpoints including safety, response rate, overall survival (OS), and patient-reported outcomes. The combination treatment’s safety profile was consistent with previous phase 3 clinical trials evaluating ramucirumab and erlotinib.
This trial was the second positive phase 3 study of ramucirumab in metastatic NSCLC. In the phase 3 REVEL study, ramucirumab plus docetaxel was compared with placebo plus docetaxel in patients with metastatic NSCLC whose cancer had progressed on or after prior platinum-based chemotherapy for locally advanced or metastatic disease. The primary endpoint of OS for this study was met.
Additionally, previously completed phase 3 studies supported approvals for ramucirumab in second-line gastric and colorectal cancer.
Ramucirumab is currently approved in the United States for use:
  • As a single agent or in combination with paclitaxel as a treatment for patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose cancer has progressed on or after fluoropyrimidine.
  • In combination with docetaxel as a treatment for patients with metastatic NSCLC whose cancer has progressed on or after platinum-based chemotherapy.
  • In combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer whose cancer has progressed on or after therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
 Detailed safety and efficacy data from the phase 3 RELAY trial will be presented at a medical meeting in 2019, according to Lilly.
Lilly’s Cyramza (ramucirumab) phase 3 RELAY trial met primary endpoint, significantly improving progression-free survival in first-line treatment of patients with metastatic EGFR-mutated non-small cell lung cancer [news release]. Eli Lilly. https://investor.lilly.com/news-releases/news-release-details/lillys-cyramzar-ramucirumab-phase-3-relay-trial-met-primary. Accessed March 12, 2019.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.
The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.
Officials with the FDA have granted approval to entrectinib (Rozlytrek, Genentech) for 2 different cancer indications.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.